Compares the efficacy of octreotide and somatostatin therapy after CRS and HIPEC in peritoneal carcinomatosis, suggesting potential benefits for patient safety.
Somatostatin and octreotide analogues appear to decrease the duration of enterocutaneous fistulas, but their application in PC patients after CRS + HIPEC might reduce SAEs.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: